ClinicalTrials.gg
RecruitingNCT07464314Updated Jun 30, 2026

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

A Phase 1 interventional study of Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine and Licensed Seasonal Influenza Vaccine in Influenza, Human+COVID-19, sponsored by GlaxoSmithKline. Recruiting at 12 sites in United States. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.

Planned enrollment
98th of 165
225 · median 324
Started
2026
with 2 others
Phase 1
22 of 187
1 open now
Registered
185th of 187
by date

Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 98th largest by planned enrollment of the 165 interventional ones that give a count, is one of 3 that started in 2026, is one of 22 in phase 1, and was the 185th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Influenza, Human by GlaxoSmithKline, or all of them as a file.
02

Study summary

This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.

03

Conditions studied

  • Influenza, Human+COVID-19

Keywords

  • Influenza
  • COVID-19
  • SARS-CoV-2
  • mRNA vaccine
  • combination vaccine
  • immunogenicity
  • older adults
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver.
  2. obtained from the participant prior to performance of any study-specific procedure.
  3. A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening.
  4. Healthy participants or medically stable patients as established by medical history and clinical examination.
  5. Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  1. Any laboratory abnormality.
  2. History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration.
  3. History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine.
  4. Current or past , unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for >5 years.
  5. Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  6. History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection.
  7. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
  8. Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
  9. History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine.
  10. History of hypersensitivity or allergic reaction to any previous mRNA vaccine.
  11. Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
  12. Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
  13. Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
  14. Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration.
  15. Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    FLU/COVm_Dose Level 1

    Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 1 (Lowest dose).

    Biological: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine

  • Experimental
    FLU/COVm_Dose Level 2

    Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 2 (Medium dose).

    Biological: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine

  • Experimental
    FLU/COVm_Dose Level 3

    Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 3 (Highest dose).

    Biological: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine

  • Active comparator
    Licensed Seasonal Influenza Vaccine Group

    Participants receive a single intramuscular administration of a licensed seasonal Flu vaccine.

    Biological: Licensed Seasonal Influenza Vaccine

  • Active comparator
    Licensed COVID-19 Vaccine Group

    Participants receive a single intramuscular administration of a licensed COVID-19 vaccine.

    Biological: Licensed COVID-19 Vaccine

Interventions

  • BiologicalInvestigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine

    Flu/COVm Vaccine with multiple dose levels (Dose Level 1, Dose Level 2, and Dose Level 3), will be administered via single intramuscular injection.

  • BiologicalLicensed Seasonal Influenza Vaccine

    License Seasonal Influenza Vaccine will be administered as a single intramuscular dose.

  • BiologicalLicensed COVID-19 Vaccine

    Licensed COVID-19 Vaccine will be administered as a single intramuscular dose.

06

What researchers measure

Primary outcomes

  1. Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities Following Administration of the Study Intervention

    The assessed toxicity grades for laboratory value abnormalities will be defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Potentially life-threatening.

    Time frame: Day 1 to Day 3

  2. Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities following Administration of Study Intervention

    Time frame: Day 1 to Day 8

  3. Number of Participants with an Increase in Toxicity Grade of Laboratory Value Abnormalities following Administration of Study Intervention

    Time frame: Day 1 to Day 29

  4. Number of Participants with Solicited Administration Site Adverse Events (AEs)

    The solicited administration site AEs considered are pain, redness, swelling and lymphadenopathy.

    Time frame: Day 1 to Day 7

  5. Number of Participants with Solicited Systemic AEs

    The solicited systemic AEs considered are fever, headache, fatigue, myalgia, arthralgia and chills.

    Time frame: Day 1 to Day 7

  6. Number of Participants with Unsolicited AEs

    An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

    Time frame: Day 1 to Day 28

  7. Number of Participants with Serious Adverse Events (SAEs)

    A SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.

    Time frame: Day 1 to Day 181

  8. Number of Participants with Adverse Events of Special Interest (AESIs)

    The following events are considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, Aminotransferase elevation; myocarditis/pericarditis within 6 weeks after study intervention administration and potential immune-mediated diseases (pIMDs).

    Time frame: Day 1 to Day 181

  9. Number of Participants with Medically Attended Adverse Events (MAAEs)

    A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional.

    Time frame: Day 1 to Day 181

Secondary outcomes

  1. Geometric Mean Titer (GMT) Of Antigen 1 Titer

    Time frame: At Day 29

  2. Percentage of Participants with Antigen 1 Seroconversion Rate (SCR)

    Time frame: Day 1 to Day 29

  3. Percentage of Participants with Antigen 1 Seroprotection Rate (SPR)

    Time frame: At Day 1 and Day 29

  4. Geometric Mean Increase (GMI) of Antigen 1 Titer

    Time frame: Day 1 to Day 29

  5. GMT Of Antigen 2 Titer

    Time frame: At Day 29

  6. Percentage of Participants with Antigen 2 SCR

    Time frame: Day 1 to Day 29

  7. GMI of Antigen 2 Titer

    Time frame: Day 1 to Day 29

  8. GMT ratio of serum neutralization titers against pseudovirus bearing spike from SARS-CoV-2 vaccine matched variant(s)

    Time frame: At Day 29

  9. Percentage of participants with seroresponse of neutralization titers against pseudovirus bearing spike from SARS-CoV-2 vaccine matched variant(s)

    Time frame: Day 1 to Day 29

  10. GMI of neutralization titers against pseudovirus bearing spike from SARS-CoV-2 vaccine matched variant(s)

    Time frame: Day 1 to Day 29

07

Study locations

12 of 12 sites recruiting
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
    Recruiting
  • GSK Investigational Site
    Little Rock, Arkansas 72204, United States
    Recruiting
  • GSK Investigational Site
    Fair Oaks, California 95628, United States
    Recruiting
  • GSK Investigational Site
    San Diego, California 92123, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33186, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
    Recruiting
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78705, United States
    Recruiting
  • GSK Investigational Site
    Charlottesville, Virginia 22911, United States
    Recruiting
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
    Recruiting
  • GSK Investigational Site
    Seattle, Washington 98104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 11, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Dec 3, 2026
CompletionEst.
Jun 3, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07464314
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Mar 9, 2026
Primary completion
Dec 3, 2026 (estimated)
Completion
Jun 3, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion